Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Abstract

Objectives: We conducted a systematic review and meta-analysis of the influence of host and viral factors on the sustained virologic response (SVR) in hepatitis C virus genotype 6 (HCV-6) patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Methods: Data were retrieved fromMedline, Embase, PubMed and the Cochrane Library for ‘genotype 6' studies published up to December 2014 and for abstracts from international scientific meetings. Inclusion criteria were efficacy of PEG-IFN+RBV based on SVR, 24- or 48-week therapy and treatment-naïve patients. Patients with hepatitis B, D and E and HIV coinfection or another concurrent liver disease were excluded. Pooled standard difference, odds ratio and confidence intervals (CIs) were calculated using a random-effect model with STATA 11. Results: Fourteen studies were included in the meta-analysis. The pooled SVR rate was 80% (95% CI: 0.78-0.83, p < 0.0001; I² = 71.2%). SVR of the PEG-IFN+RBV-treated HCV-6 patients was markedly higher than that of HCV-1 patients (80.1 vs. 55.3%). The SVR rate was significantly higher for the 48- than the 24-week treatment, but not different among HCV-infected patients with rs12979860 and ss469415590 polymorphisms of the ILFN4 gene (80.6% CC vs. 66.7% non-CC, p = 0.593; 81.1% TT/TT vs. 60% non-TT/TT, p = 0.288). Gender and type of PEG-IFN did not affect SVR rates. Conclusions: Treatment outcomes for HCV-6 patients are superior to those for HCV-1 patients and comparable to those of HCV-2 and HCV-3 patients, especially at 48 weeks. The level of fibrosis affects treatment outcome, but SVR rates are not significantly different between genders. IL28B and IFNL4 polymorphisms are not significantly associated with HCV-6 treatment outcome.

Evaluation of the implementation effect of hepatitis C medical insurance reimbursement policy in China: A RWS based on medical institutions

“…In this study, the SVR rate of patients using the traditional interferon treatment was only 65.2%, which was slightly lower than that of relevant studies and related statistics at within China and abroad ( 1 , 21 ): the SVR rate of patients using the DAA drug treatment was 97.4%, which was basically consistent with the statistics of other relevant real-world clinical studies and guidelines ( 6 , 22 ), further verifying the effectiveness of DAA drugs. Among the patients who were cured, the average treatment time of patients using DAA drugs was 2.65 months, which was only one-sixth of the traditional interferon treatment time.…”

Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar

“…Different direct-acting antiviral (DAA) therapies appeared to have various sustained virologic response (SVR) for different HCV genotypes. A systematic review and meta-analysis revealed that SVR of the PEG-IFN+RBV regimen to HCV genotype 6 was similar to genotypes 2 and 3, but higher than genotype 1 (Thong et al, 2015). The safety and efficacy of SOF-based DAA regimens for treatment of HCV genotype 6 were well demonstrated by some studies conducted in China and the United States (Wong et al, 2017; Hu et al, 2018; Wu et al, 2019).…”

Correlation of interferon-lambda 4 ss469415590 with the hepatitis C virus treatment response and its comparison with interleukin 28b polymorphisms in predicting a sustained virological response: a meta-analysis

“…33 Consistent with the present results, the authors of that meta-analysis showed that IFNL4 rs368234815 can predict SVR in HCV patients, which is independent of HCV genotype, patient ethnicity, and treatment regimen. A considerable number of studies have focused on this, 34,35 and the role of IFNL4 becomes more and more evident.…”